



Date: May 14, 2026

To The Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 <b>Stock Code : INDOCO</b>	To The Listing Department <b>Bombay Stock Exchange Limited</b> Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Stock Code : 532612</b>
---	--

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 –Completion of Inspection at Indoco Remedies Limited Baddi Unit-I**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Malta Medicines Authority had inspected Company's manufacturing facility for solid oral dosage form (Unit I) located at Baddi ("Facility"), from January 29, 2026 to February 03, 2026.

The Facility has received EU GMP certification from the Malta Medicines Authority confirming that the Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Please find enclosed herewith press release in this regard. Kindly take the above information on record.

**Thanking you,  
Yours faithfully,  
For Indoco Remedies Limited**

**Ramanathan Hariharan  
Company Secretary & Head Legal**





## PRESS RELEASE

### **Indoco Remedies successfully clears Malta Medicines Authority audit**

**Mumbai, May 14, 2026:** Indoco Remedies Ltd. has announced today that the Malta Medicines Authority had inspected the Company's manufacturing facility for solid oral dosage form (Unit I) located at Baddi from January 29, 2026, to February 3, 2026.

The facility has received EU GMP certification from the Malta Medicines Authority confirming that it complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Commenting on this development, **Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd.** said, "This approval from the Malta Medicine Authority further reflects Indoco's strong commitment to quality, compliance and adherence to global regulatory standards. We are focused on maintaining the highest quality standards while catering to our customers in India and globally."

#### **About Indoco Remedies Limited:**

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopham, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Otorex, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69 etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

#### **For Media enquiries please contact:**

Tel. | +91 22 62871000

E-mail: [corpcom@indoco.com](mailto:corpcom@indoco.com)